Bowers Daniel C, Mulne Arlynn F, Weprin Bradley, Bruce Derek A, Shapiro Kenneth, Margraf Linda R
Department of Pediatrics, UT Southwestern Medical School at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9063, USA.
Pediatr Neurosurg. 2002 Aug;37(2):57-63. doi: 10.1159/000065106.
Few reports exist describing the progression-free and overall survival of children with low-grade (WHO grade II) oligodendrogliomas treated uniformly with aggressive surgery but without adjuvant chemotherapy or radiation therapy. Furthermore, significant prognostic features, including the MIB-1 labeling index (LI), have not been reported for children with oligodendrogliomas. The medical records of 20 consecutive patients with low-grade oligodendrogliomas were reviewed. All patients had been treated with aggressive surgical resection. Adjuvant chemotherapy and radiation therapy were reserved for radiographic or clinical progression. These patients have been followed for a median of 5.5 years (range 0.5-11.5 years) after diagnosis. To date, there have been no patient deaths. Six of the 20 patients experienced tumor progression at a median of 2.2 years (range 0.4-4.8 years) following the initial surgery. The MIB-1 LI was infrequently greater than 5. Of several prognostic factors for subsequent tumor progression that were examined, only tumors located within the parietal lobes were associated with a worse progression-free survival. Other risk factors, including presenting symptoms, age at diagnosis, MIB-1 LI and the extent of tumor resection, were not associated with an increased frequency of tumor progression.
很少有报告描述采用积极手术但未进行辅助化疗或放疗的低级别(世界卫生组织二级)少突胶质细胞瘤患儿的无进展生存期和总生存期。此外,少突胶质细胞瘤患儿的显著预后特征,包括MIB-1标记指数(LI),尚未见报道。回顾了20例连续的低级别少突胶质细胞瘤患者的病历。所有患者均接受了积极的手术切除。辅助化疗和放疗用于影像学或临床进展的情况。这些患者在诊断后中位随访5.5年(范围0.5 - 11.5年)。迄今为止,尚无患者死亡。20例患者中有6例在初次手术后中位2.2年(范围0.4 - 4.8年)出现肿瘤进展。MIB-1 LI很少大于5。在检查的几个后续肿瘤进展的预后因素中,只有位于顶叶的肿瘤与较差的无进展生存期相关。其他危险因素,包括首发症状、诊断时年龄、MIB-1 LI和肿瘤切除范围,与肿瘤进展频率增加无关。